On November 2, the State Food and Drug Administration announced that the bismuth potassium citrate capsule produced by Hunan Warner Pharmaceutical Co., Ltd. passed the consistent evaluation and was approved for the first time in the country. The "one-stop" clinical study of this variety was completed by Duzheng Biology (The cooperative co-construction unit Changsha Central Hospital was responsible for the clinical study, the leading medicine was responsible for recruitment and SMO service, and the data management and statistical analysis of weights and counters data).
Bismuth potassium citrate capsules by inhibiting the protease produced by helicobacter pylori, urokinase and phospholipase body function, and antibiotics, can the eradication of helicobacter pylori, with inhibition of gastric acid secretion of proton pump inhibitors and H2 receptor antagonist quadruple scheme, as the eradication of helicobacter pylori remedial treatment failure, It is often used for chronic gastritis and relief of stomach pain, burning sensation and acid reflux caused by excessive gastric acid.
Duzheng Biotech provides one-stop clinical evaluation services for drugs, medical devices and diagnostic reagents for global biomedical enterprises. Currently, the first official BE equivalent project in China has been completed, including Pantoprazole sodium enteric-coated tablet, rabeprazole sodium enteric-coated tablet, esomeprazole magnesium enteric-soluble dry suspension, donepezil hydrochloride tablet, etc., among which pantoprazole sodium enteric-coated tablet has been approved by the first and second companies in China, and Donepezil hydrochloride tablet has been approved by the first company in China.
Duzheng Bio will continue to adhere to the "customer-centric" service concept, to help global pharmaceutical enterprises out of the encircling, curve overtaking!